-
CANbridge Secures Global Rights to Second-Generation Gene Therapy for SMA
•
China – based biopharma CANbridge Pharmaceuticals Inc. (HKG: 1228) has unveiled a license deal to secure exclusive global rights to a novel, second – generation gene therapy for spinal muscular atrophy (SMA) from UMass Chan Medical School in the United States. The deal includes all development, manufacturing, and commercialization rights…
-
Transcenta’s TST003 Receives Clinical Trial Approval in China and US
•
China – based biopharma Transcenta Holding Ltd (HKG: 6628) has announced that it has received clinical trial approval in China for TST003, its potential first – in – class monoclonal antibody (mAb) targeting Gremlin1. The drug candidate has already received IND clearance from the US FDA in September this year,…
-
Henlius’ Hanbeitai Gains NMPA Approval for Expanded Indications
•
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that the National Medical Products Administration (NMPA) has approved a supplementary Biologic License Application (sBLA) for its biosimilar Hanbeitai (bevacizumab). The approval expands the indications for which Hanbeitai can be used, now including cervical cancer, epithelial ovarian cancer, fallopian tube cancer, and…
-
Sihuan’s Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline
•
China – based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced the successful completion of a Series A + financing round for its subsidiary Hui Sheng Bio – pharmaceutical Co., Ltd. The funding round was led by Jilin Baixing Bairong Investment Center, with additional contributions from Jilin Province Private…
-
HutchMed Completes Enrollment for Phase III ESLIM-01 Study of Sovleplenib in ITP
•
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment in the ESLIM – 01 study, a pivotal Phase III trial assessing the efficacy and safety of sovleplenib in treating adult patients with primary immune thrombocytopenia (ITP) in China. This marks a significant milestone in…
-
RemeGen’s RC48 Gains NMPA Approval for Phase II Study in Bladder Cancer
•
China – based biopharmaceutical company RemeGen Ltd (HKG: 9995) has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase II study of its antibody – drug conjugate (ADC) candidate RC48 (disitamab vedotin). The study will assess the efficacy and safety of RC48…
-
Apeloa and Simcere Partner for CDMO Services and R&D Collaboration
•
China – based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced a partnership agreement with compatriot firm Simcere Pharmaceutical Group (HKG: 2096). The collaboration aims to enhance the research and development (R&D) and manufacturing capabilities of both companies through strategic alignment. Details of the…
-
Sino Biopharmaceutical’s CTTQ Partners with ProteLight for Antibacterial Peptide PL-5
•
China – based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd (CTTQ) has entered into an exclusive commercial cooperation agreement with compatriot firm Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. Under the terms of the agreement, CTTQ will be responsible for…
-
Inscinstech Raises RMB 150 Million in Series A+, B, and B+ Rounds
•
Inscinstech Inc., a leading specialist in biological separation technology based in Suzhou, China, has successfully raised a total of RMB 150 million (USD 21.73 million) across its Series A+, B, and B+ financing rounds. The funding rounds were led by ESCO Lifesciences Group, Luxin Venture Capital, and Qiming Venture Partners,…
-
Everest Medicines Outlines Strategic Plans for Expansion and Growth
•
China – based biopharmaceutical company Everest Medicines (HKG: 1952) has announced its strategic plans for the next two years and beyond as it progresses toward becoming a fully – integrated biopharmaceutical company. The company aims to develop capabilities across the full biotechnology value chain, including in – house discovery, in…
-
Zai Lab Appoints Dr. Rafael Amado as President of Cancer R&D
•
Chinese biopharmaceutical company Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the appointment of Dr. Rafael G. Amado as President and Global Head of Cancer Research and Development (R&D), effective December 30, 2022. Dr. Amado will join the company’s management committee as a core member, reporting directly to Dr.…
-
Jiangxi Jemincare Gains FDA Approval for Clinical Trial of JYB1907 in Solid Tumors
•
China – based Jiangxi Jemincare Group has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a clinical study for its Category 1 drug JYB1907. The monoclonal antibody (mAb) targets glycoprotein A dominant repeat (GARP) and transforming growth factor – β1 (TGF –…
-
Mabwell Receives NMPA Approval for Clinical Trial of 9MW3011 in Rare Diseases
•
China – based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study assessing its Category 1 drug candidate 9MW3011 for the treatment of β – thalassemia and polycythemia vera. The drug, which already…
-
Staidson’s Anti-C5a Monoclonal Antibody STSA-1002 Accepted for NMPA Review
•
China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced that the clinical trial filing for its injectable STSA-1002, an anti-human complement protein C5a (hC5a) monoclonal antibody (mAb) for use in acute respiratory distress syndrome (ARDS), has been accepted for review by the National Medical Products Administration (NMPA). About ARDS…
-
Guangdong Raynovent Biotech Secures RMB 370 Million in Series C Financing
•
Guangdong Raynovent Biotech Co., Ltd, a controlling subsidiary of China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), has reportedly raised RMB 370 million (USD 53.72 million) in a Series C financing round. The round was co-led by Yide Private Equity Investment Fund Management (Guangzhou) Co., Ltd and Efung Capital, with…
-
Hengrui Pharmaceuticals Appoints Dr. Jiang Ningjun as Deputy General Manager and CSO
•
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced the appointment of Dr. “Frank” Jiang Ningjun as its deputy general manager and chief strategy officer (CSO). Dr. Jiang will be tasked with overseeing clinical studies and driving business expansion. Moving forward, Sun Piaoyang, Zhang Lianshan, and Dr. Jiang Ningjun will form…
-
Junshi Biosciences’ CGRP Monoclonal Antibody JS010 Accepted for NMPA Review
•
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that the clinical trial filing for JS010, its in-house developed CGRP monoclonal antibody drug candidate for treating migraine, has been accepted for review by the National Medical Products Administration (NMPA) in China. About CGRP and JS010CGRP is a neuropeptide composed of…
-
BeiGene’s Tislelizumab Receives NMPA Review for First-Line HCC Indication
•
BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has revealed that a supplementary Biologic License Application (sBLA) for its programmed death-1 (PD-1) inhibitor tislelizumab has been accepted for review by the National Medical Products Administration (NMPA). The latest prospective indication is for the drug’s use in first-line unresectable or metastatic hepatocellular…
-
Immunohead Biotech Raises RMB 200 Million in Series A+ Financing Round
•
Immunohead Biotechnology Co., Ltd, a cell therapy developer based in Suzhou, has reportedly raised close to RMB 200 million (USD 28.89 million) in a Series A+ financing round. The round was led by SDIC Venture Capital, with participation from the Bio-Town Equity Investment Fund. The proceeds will be used to…
-
Biocytogen and Hansoh Enter Antibody Collaboration and Licensing Agreement
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an antibody collaboration, assignment, and exclusive license agreement with compatriot firm Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692). Under the agreement, Biocytogen will provide a license to Hansoh to use selected fully human antibody molecules against a designated target for global development,…
